Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.

Pharmacogenetics - 1 Mar 2002

Kirchheiner Julia, Bauer Steffen, Meineke Ingolf, Rohde Wolfgang, Prang Verena, Meisel Christian, Roots Ivor, Brockmöller Jürgen

Abstract excerpt

Tolbutamide is known to be metabolized by cytochrome P450 2C9 (CYP2C9), and the effects of the CYP2C9 amino acid polymorphisms *2 (Arg144Cys) and *3 (Ile359Leu) could be important for drug treatment with tolbutamide and for use of tolbutamide as a CYP2C9 test drug. Tolbutamide pharmacokinetics and plasma insulin and glucose concentrations were studied in 23 healthy volunteers with all six combinations of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Hypoglycemic Agents

Share to Mixed Function Oxygenases

Share to Population Surveillance

Share to Steroid 16-alpha-Hydroxylase

Share to Steroid Hydroxylases

Source

Identifiers

PMID: 11875364
DOI: 10.1097/00008571-200203000-00004

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.PMID 11875364Read ↗

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.Semantic proximity Read ↗

Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.Semantic proximity Read ↗

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.Semantic proximity Read ↗

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Semantic proximity Read ↗

Relationship of P450 2C9 genetic polymorphisms in Chinese and the pharmacokinetics of tolbutamide.Semantic proximity Read ↗

Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers.Semantic proximity Read ↗

CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response.Semantic proximity Read ↗

Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus.Semantic proximity Read ↗

Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants.Semantic proximity Read ↗

In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.Semantic proximity Read ↗

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.Semantic proximity Read ↗

Estimation of Interindividual Variability of Pharmacokinetics of CYP2C9 Substrates in Humans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.